Key Articles, Guidelines, and Consensus Papers Relative to the Treatment of Dyslipidemias—2005
dc.contributor.author | Ito, Matthew K. | en_US |
dc.contributor.author | Cheung, Rebecca J. | en_US |
dc.contributor.author | Gupta, Eric K. | en_US |
dc.contributor.author | Birtcher, Kimberly K. | en_US |
dc.contributor.author | Chong, Pang H. | en_US |
dc.contributor.author | Bianco, Theresa M. | en_US |
dc.contributor.author | Bleske, Barry E. | en_US |
dc.date.accessioned | 2012-03-16T15:53:49Z | |
dc.date.available | 2012-03-16T15:53:49Z | |
dc.date.issued | 2006-07 | en_US |
dc.identifier.citation | Ito, Matthew K.; Cheung, Rebecca J.; Gupta, Eric K.; Birtcher, Kimberly K.; Chong, Pang H.; Bianco, Theresa M.; Bleske, Barry E. (2006). "Key Articles, Guidelines, and Consensus Papers Relative to the Treatment of Dyslipidemias—2005." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 26(7). <http://hdl.handle.net/2027.42/90074> | en_US |
dc.identifier.issn | 0277-0008 | en_US |
dc.identifier.issn | 1875-9114 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/90074 | |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.subject.other | Hypertriglyceridemia | en_US |
dc.subject.other | Dyslipidemia | en_US |
dc.subject.other | Cholesterol | en_US |
dc.subject.other | Guidelines | en_US |
dc.subject.other | Hypercholesterolemia | en_US |
dc.subject.other | Coronary Heart Disease | en_US |
dc.title | Key Articles, Guidelines, and Consensus Papers Relative to the Treatment of Dyslipidemias—2005 | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | College of Pharmacy, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | College of Pharmacy, Oregon State University, Portland Program at Oregon Health and Science University, Portland, Oregon | en_US |
dc.contributor.affiliationother | School of Pharmacy, Loma Linda University, Loma Linda, California | en_US |
dc.contributor.affiliationother | School of Pharmacy, Western University, Pamona, California | en_US |
dc.contributor.affiliationother | College of Pharmacy, University of Houston, Houston, Texas | en_US |
dc.contributor.affiliationother | Department of Pharmacy, John H. Stroger, Jr. Hospital, Chicago, Illinois | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/90074/1/phco.26.7.939.pdf | |
dc.identifier.doi | 10.1592/phco.26.7.939 | en_US |
dc.identifier.source | Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | en_US |
dc.identifier.citedreference | Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002; 106: 3143 – 421. | en_US |
dc.identifier.citedreference | Pearson, T.A., Laurora, I., Chu, H., et al. The lipid treatment assessment project (L‐TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid‐lowering therapy and achieving low‐density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459 – 67. | en_US |
dc.identifier.citedreference | Genest, J.. Lipoprotein disorders and cardiovascular risk. J Inherit Metab Dis 2003; 26: 267 – 87. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.